TABLE 3.
Bedaquiline MICs against M. tuberculosis isolates based on subtypes of resistance to other antituberculous drugsa
| Resistance subtype and DST medium | N | BDQ MIC (μg/ml) |
Susceptibility (%) |
|||||
|---|---|---|---|---|---|---|---|---|
| MIC range | MIC90 | MIC95 | ECV | S | ATU/I | R | ||
| 7H9 broth | ||||||||
| DS-TB | 137 | ≤0.008–0.5 | 0.12 | 0.12 | 0.12 | 97.8 | 1.5 | 0.7 |
| MDR-TB (all) | 5,036 | ≤0.008–2 | 0.12 | 0.12 | 0.12 | 97.9 | 1.5 | 0.6 |
| MDRH&R-TB | 2,969 | ≤0.008–0.5 | 0.12 | 0.12 | 0.12 | 98.1 | 1.6 | 0.3 |
| pre-XDRFQ-TB | 1,155 | ≤0.008–1 | 0.12 | 0.12 | 0.12 | 97.9 | 1.2 | 0.8 |
| pre-XDRSI-TB | 277 | ≤0.008–0.5 | 0.12 | 0.12 | 0.12 | 98.2 | 1.1 | 0.7 |
| XDR-TB | 635 | ≤0.008–2 | 0.12 | 0.12 | 0.12 | 97.0 | 1.7 | 0.9 |
| Agar | ||||||||
| DS-TB | 100 | ≤0.008–0.12 | 0.06 | 0.12 | 0.25 | 100 | 0 | |
| MDR-TB (all) | 4,614 | ≤0.008–≥4 | 0.12 | 0.12 | 0.25 | 98.8 | 0.8 | 0.4 |
| MDRH&R-TB | 2,640 | ≤0.008–1 | 0.12 | 0.12 | 0.25 | 99.0 | 1 | |
| pre-XDRFQ-TB | 1,103 | ≤0.008–1 | 0.12 | 0.25 | 0.25 | 99.0 | 1.0 | |
| Pre-XDRSI-TB | 256 | ≤0.008–1 | 0.12 | 0.12 | 0.25 | 98.8 | 1.2 | |
| XDR-TB | 615 | ≤0.008–≥4 | 0.12 | 0.25 | 0.25 | 97.6 | 2.4 | |
DST, drug susceptibility testing; DS-TB, drug-susceptible tuberculosis; ECV, epidemiological cutoff value; MDRH&R-TB, MDR-TB limited to isoniazid and rifampin resistance; MIC90, MIC required to inhibit the growth of 90% of M. tuberculosis isolates; MIC95, MIC required to inhibit the growth of 95% of M. tuberculosis isolates; pre-XDRFQ-TB, pre-extensively drug (fluoroquinolone)-resistant tuberculosis (MDR-TB with resistance to any fluoroquinolone); pre-XDRSI-TB, pre-extensively drug (second-line injectable)-resistant tuberculosis (MDR-TB with resistance to any second-line injectable); XDR-TB, extensively drug-resistant tuberculosis (MDR-TB with resistance to any fluoroquinolone and any second-line injectable).